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ABSTRACT 
Objective: The main objective of the present research work was to develop systematically the Self Micro Emulsifying Drug Delivery system of BCS 
Class IV drug in a Quality by Design framework. 
Methods: The quality by design-based formulation development proceeds with defining the Quality Target Product Profile and Critical Quality 
Attributes of dosage form with appropriate justification for the same. The statistical Mixture design was used for the development of the 
formulation. The independent variables selected for the design were Oleic acid, Labrasol and PEG 6000, whereas droplet size (nm), emulsification 
time (sec), % drug loading and % drug release at 15 min were considered as the potential quality attributes of the Self Micro Emulsifying System. 
The eight different batches of Etravirine-Self Micro Emulsifying systems (ETV-SMEDDS) were prepared and checked for the Critical Quality 
Attributes. The simultaneous optimization of the formulation was done by the global desirability approach.  
Results: The characterization report obtained for all the different batches of formulation was analyzed statistically by fitting into regression models. 
The statistically significant models determined for droplet size (nm) (R2= 0.96 and p-0.1022), emulsification time (sec) (R2= 0.99 and p-0.0267), % 
drug loading (R2= 0.93 and p-0.1667) and % drug release at 15 min (R2
Conclusion: The QbD approach utilized during the development of ETV-SMEEDS facilitated the identification of Critical Material Attributes and 
their significant impact on the Critical Quality Attributes of SMEDDS. The concept of building quality into product through the QbD application was 
utilized successfully in the formulation development. 
= 0.96 and p-0.0911) and were statistically significant. The maximal global 
desirability value obtained was 0.9415 and the value indicates, the selected factors and responses have a good correlation and are significant 
enough for optimization and prediction of best formulation. 
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INTRODUCTION 
Pharmaceutical industry is the highly regulated industry and it is 
controlled by the authoritative regulatory bodies. The regulatory 
agencies emphasizes on the quality of pharmaceutical products. 
Quality can be planned and majority of the quality deficiency occur 
in the way the process is planned and developed [1]. The concept of 
Quality by Design and its application in the product development 
was introduced by the quality expert Joseph Moses Juran. The 
principles of QbD have been used in every industry to improve 
quality of the product and process [2, 3].  
Among the second-generation Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs), Etravirine is the first drug and 
has been recently used for the treatment of HIV infection. Etravirine 
is used more extensively in comparison to other available first 
generation NNRTIs due to its activity against NNRTI-resistant HIV-1 
[4]. The drug shows its action by binding directly to the reverse 
transcriptase of HIV-1 and consequently blocks the activity of DNA-
dependent and RNA-dependent polymerase [5]. Etravirine belongs 
to Biopharmaceutical Classification System (BCS) IV and the limited 
therapeutic potential is due to its low solubility and permeability 
characteristics. There is a requirement for the development of more 
bioavailable formulation of ETV to facilitate better clinical outcomes. 
Self-Micro Emulsifying Drug Delivery (SMEDDS) system is the 
variant of a lipid-based formulation used for the development of 
poorly water-soluble drugs. SMEDDS comprises oil, surfactant and 
cosurfactant, sometimes cosolvent [6]. The in vivo emulsification of 
SMEDDS takes place once it comes in contact with the GI fluids 
under the mild agitation provided by the GI motility. SMEDDS finds 
its potential application in the enhancement of oral bioavailability of 
poorly water-soluble drugs belonging to BCS Class II and IV [7, 8]. In 
the present study, the concept of building quality into product 
through the QbD application was utilized in the development of 
Etravirine Self Micro Emulsifying Drug Delivery System (ETV-
SMEDDS). 
MATERIALS AND METHODS 
Materials 
Etravirine was received as gift sample form Hetero Pvt Ltd, 
Hyderabad, India. Labrasol, Maisine CC, Labrafil M 1944 CS, Capryol 
90 and Transcutol HP were obtained as gift samples from Gattefosse, 
Saint-Priest Cedex, France. Span 80, Span 20, Oleic acid and PEG 
6000 were purchased from Sigma-Aldrich, Germany. All other 
chemicals used in the present study were of analytical grade. 
Methods 
Defining the quality target product profile (QTPP) and critical 
quality attributes (CQA) 
The product development through QbD approach advocates on 
defining the QTPP and it is one of the prerequisites to deliver 
therapeutic benefits as per label claim. The QTPP for liquid SMEDDS 
was defined and it is based on the patient-centric (emulsification 
time, globule size, drug release) and product centric (zeta potential) 
quality attributes of the drug product. The CQAs were identified 
from QTPP and they were interlinked to give the desired quality, 
safety and efficacy to the product, which shows prominent changes 
when QTPP are altered [9, 10]. The QTPP and CQAs were listed in 
the table 1 and 2, respectively. 
Risk assessment 
Risk assessment is a combined effort of identifying and evaluating 
the factors that may have an impact on the product’s CQAs. The risk 
assessment tools help in identifying and mitigating the risks and 
prioritize the risk as high, medium or low based on the impact level. 
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The two qualitative tools used in the present study were Fishbone 
diagram and Risk Estimation Matrix table. Fishbone diagram (fig. 1) 
was constructed by using JMP Ver 13.2 software. Fishbone diagram 
depicts the cause and sub causes affecting the CQAs and risk 
assessment matrix helps in categorizing the risk. The table 3 
represents the risk estimation matrix for ETV-SMEDDS. 
  
Table 1: Quality target product profile of ETV-SMEDDS 
QTPP elements  Target  Justification  
Dosage type  Lipid-based formulation  Enhancement of Bioavailability of poorly water-soluble drugs 
Dosage form  Capsule  Ease of administration  
Dosage strength  50 mg  Required to show the therapeutic action at the target site  
Route of administration  Oral  Most convenient route for AIDS patients (Patient acceptability)  




Physical attributes Formulation must meet the compendial quality standards 
Droplet size 
Transmittance 





Stability  As per the conditions of ICH 
Q1B Long term stability studies  
To maintain the therapeutic level of the drug during the shelf life 
period  
Pharmacokinetic parameters Tmax, Cmax, AUC  Maximum drug levels in systemic circulation helps to improve the 
therapeutic efficiency  
 
Table 2: Critical quality attributes of ETV-SMEDDS 
Quality attributes of product  Target  CQA  Justification  
Physical 
Attributes 
Colour Acceptable to 
patient  
No  The physical attributes were not directly related to safety and efficacy of 
the product; hence they were considered non-critical. The product will be 
enclosed in a capsule shell.  
Odor 
Appearance 
Drug content (mg)  NLT 50 mg per dose  Yes  50 mg per unit dose of Etravirine is essential to fight against CD4 viral load  
Transmittance (%)  >90%  Yes  Better clarity of the formulation confirms the minimization of droplet size  
Droplet size (nm)  <200 nm  Yes  The stability of the product and better penetrability through gastro 
intestinal membrane ensured by the smaller and consistent globule size 
Emulsification proficiency (seconds)  <120  Yes  Emulsification time has the direct correlation with onset of action and 
influences the size of dispersed particles  
Drug release at 15 min  >80%  Yes  Faster the release of drug from the formulation, earlier the onset of action  
 
 
Fig. 1: Fishbone diagram depicting causes and sub causes affecting ETV-SMEDDS quality attributes 
 
Table 3: Risk estimation matrix table for ETV-SMEDDS 
  Critical quality attributes 














Drug Low Low Low Low Low High Medium 
Oleic acid High High High High High High High 
Labrasol High High High High High High High 
PEG 6000 High High High High High High High 
Process 
Attributes 
Stirring Time High Medium Low Low Low Low Low 
Stirring Speed Medium Medium Low Low Low Low Low 
Stirring Temperature Medium Medium Medium Medium Medium Low Low 
Sonication High Medium Medium Medium Medium Low Low 
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Solubility study  
The solubility of Etravirine in various oils, surfactants and 
cosurfactants was checked. To perform the solubility study, the 
excess amount of drug was added to each excipient (2 ml) and 
vortexed for 48 h to maintain the equilibrium. The samples were 
centrifuged at 3000 rpm for 15 min. The supernatant liquid was 
filtered through a 0.45 µm Millipore®
Construction of pseudo ternary phase diagram 
 filter and suitably diluted with 
a solvent mixture of Methanol and Water (1:9) and analyzed at 310 
nm using UV Spectrophotometer (UV 1800 Shimadzu). Studies were 
carried out in triplicates to assure accuracy [11]. 
The objective of constructing Pseudo ternary phase diagrams was to 
check the concentration ranges of SMEDDS components which could 
give nano or microemulsion regions. The phase diagrams were 
constructed by using Prosim®
Design of experiments 
 Ternary plot software. The oil (Oleic 
acid), surfactant (Labrasol) and cosurfactant (PEG 6000) were 
selected based on the solubility studies. Surfactant and Cosurfactant 
(Smix) were prepared in different ratios (1:1, 2:1 and 3:1). A varying 
proportion of Oil and Smix were mixed (1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 
7:3, 8:2, and 9:1 respectively) and homogenized by using a vortex 
mixer. The double-distilled water was added to the mixture at an 
increment of 5% in the range of 5 to 95 % of total volume, vortexed 
and allowed to equilibrate [12]. 
Design of Experiments (DoE) deals with planning, analyzing and 
interpreting the factors that control the responses. Mixture design 
was chosen from the classical category of DoE software based on the 
convenience and minimal number of runs given by design [13]. For 
this study, JMP ®
 
 Ver 13.2 software was used to create the 
formulation plan after choosing the appropriate oil, surfactant and 
cosurfactant. The mixture design was used in the development of 
SMEDDS formulation because the factors are the proportion of 
blend. The independent variables (material attributes) considered in 
the design were Oleic acid, Labrasol and PEG 6000 (table 4). The 
droplet size (nm), emulsification time (sec), % drug loading and % 
drug release at 15 min were the dependent variables chosen for the 
study (table 4). Through the mixture design total of eight different 
batches of SMEDDS formulations were obtained and subjected for 
checking the CQAs. 
Table 4: Independent and dependent variables and their limits in mixture design 
Independent variables 
Factors Role Lower value Higher value 
Oleic Acid Mixture  0.1 0.23 
Labrasol Mixture 0.577 0.675 
PEG 6000 Mixture 0.193 0.225 
Dependent variables 
Variables Goal Lower limit Higher limit 
Droplet Size in nm Minimize 100 500 
Emulsification time in Sec Minimize 20 60 
% Drug loading Maximize 90 100 
% Drug release at 15 min  Maximize 70 100 
 
Preparation of liquid SEDDS formulation 
Eight different batches of ETV-SMEDDS were prepared as per the 
mixture design. The formulations were developed by dissolving 50 
mg of drug in the mixture of Oleic acid, Labrasol and PEG 6000 and 
followed by heating at 40 °C in a water bath. The same mixture was 
then vortexed until it became clear and transparent. The prepared 
formulations were stored in ambient temperature until use [14]. 
Evaluation of liquid SMEDDS 
Droplet size analysis 
The droplet size of the prepared ETV-SMEDDS was checked by 
diluting the sample with double distilled water at the ratio of 1:100 
(v/v). The mean droplet size and Polydispersity index (PDI) was 
measured in triplicates by photon correlation spectroscopy using 
Malvern Zetasizer Nano-ZS (Malvern Instruments, United Kingdom) 
[15, 16]. 
Emulsification time 
The self-emulsification time was determined by using USP Type II 
dissolution apparatus (LABINDIA, DS 8000, MUMBAI).1 ml of the 
formulation was added dropwise into a 500 ml of double-distilled 
water, maintained at the temperature of 37±0.5 °C, under mild 
agitation of paddle (50 rpm). Each formulation is observed visually 
for clarity, homogenization and for precipitation of drug. The time 
taken by each formulation to form a clear emulsion was noted in 
seconds [17]. 
Drug loading  
The pre-concentrated SMEDDS equivalent to 50 mg of Etravine was 
taken and the drug was extracted by using a small quantity of 
methanol. The volume was made up to 100 ml with double distilled 
water. From the stock solution, 0.1 ml was withdrawn and diluted 
up to 10 ml with double distilled water. The resultant solution 
absorbance was measured at 310 nm by UV-Visible 
Spectrophotometer (UV 1800, Shimadzu). The drug content 
measurements were carried out in triplicates [18]. 
In vitro drug release studies 
In vitro drug release studies were executed in the phosphate buffer 
(pH 6.8) with 2% Tween 20 using USP-II basket type dissolution 
apparatus. The temperature of the medium was maintained 37 
°C±0.5 and rpm was set to 50. The SMEDDS formulation equivalent 
to 50 mg of drug was filled into the hard gelatin capsules. The 
capsules were placed inside the jars with the help of stainless steel 
sinkers to avoid buoyancy. Samples were withdrawn from the 
dissolution jars at the time intervals of 5, 10, 15, 30, 45 and 60 min 
and further diluted with phosphate buffer and analyzed by UV-
Visible Spectrometer (UV 1800, Shimadzu) at 310 nm [19]. 
Model evaluation and validation 
Model evaluation was carried out by incorporating the various 
responses obtained for all the eighth formulations into the design. 
The data of Droplet size (nm), Emulsification time (sec) % Drug 
loading and % Drug release at 15 min were statistically analyzed by 
various multiple regression models. The validation of the design was 
carried out with the help of Ternary Mixture Profiler. The profilers 
consist of ternary plot, factor settings with the controls and 
response settings and its controls. The verification batch was 
prepared as per the Ternary Mixture Profiler and checked for the 
predicted CQAs. The lack of differences in the variance between 
observed and predicted responses indicates the goodness of fit. 
Optimization of formulation 
The simultaneous optimization of the formulation was done by using 
the Prediction profiler. Prediction Profiler gives a visual way to see 
how changing one factor setting impacts the response as well as 
impacts the other factors in the model. The global desirability 
function obtained for the model was taken as a key component for 
optimization. The overall desirability value shows on a scale of zero 
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to one. Optimized formulation (OF) was prepared based on the 
prediction profiler and was evaluated for the responses. The zeta 
potential of the optimized formulation was measured by using 
Malvern Zetasizer Nano-ZS. 
RESULTS AND DISCUSSION 
Although several works have reported the formulation of ETV 
SEDDS by OFAT approach either to enhance bioavailability or to 
attain other formulation goals [20]. A rigorous development of ETV-
SMEDDS by QbD approach was not present. Developing sparsely 
bioavailble drugs in a QbD approach affords the researcher to get 
sophisticated understanding of risk associated with the formulation 
and methods to overcome it. The OFAT method reported by earlier 
researchers might not be tenable for replication; however, this 
approach adopted by us is rigorous in its approach to development 
following the QbD paradigm and establishes the likely multivariate 
relationship for the factors and responses considered for the 
formulation and its likely outcome in statistically tenable manner.  
Risk assessment  
The dosage form development under QbD framework involves 
material evaluation as well as process attributes which have a 
greater impact on the quality of the drug. The two qualitative risk 
assessment tools which were used in the present study were 
Ishikawa diagram and Risk Estimation matrix table. Ishikawa 
diagram is also called Cause-and-effect/Fishbone diagram, by using 
this diagram, we identified all the contributing root causes likely to 
be causing problems in ETV-SMEDDS. In the risk assessment matrix 
table, each factor was assigned with a risk grade of low, medium or 
high as per priority and the factors with high risk were selected for 
the design of the experiment in order to arrive at design space. 
Solubility study 
The solubility of Etravirine in various oils, surfactants and co-
surfactants was checked and the report obtained is presented in fig. 
2. The highest solubility of a drug in any lipid would augment its 
drug loading capacity. Accordingly, on the basis of maximum 
solubility, Oleic acid (31.2±1.9 mg/ml) was selected as oil phase in 
the formulation of SMEDDS and it was also reported that oleic acid 
enhances the intestinal absorption of the drug, which leads to the 
lymphatic transport of the drug. Labrasol (74 mg/ml) was selected 
as surfactant based on both emulsification efficiency and solubility 
of Etravirine. Co-surfactants increase the interfacial fluidity by 
penetrating into the surfactant film creating void space among 
surfactant molecules. Among various cosurfactants, PEG 6000 
(52.4±1.5 mg/ml) was selected for the formulation development. 
 
 
Fig. 2: Solubility study report (mean±SD, n=3) 
 
 
Fig. 3: Pseudo ternary phase diagram 
 
Pseudo ternary phase diagram 
The main objective is to study the relationship between the phase 
behavior relative to the composition, which helps in determining the 
concentration range of components for the formation of an 
emulsion. In order to apply DOE for the formulation, it was 
necessary to identify the highest self-emulsifying region from 
ternary phase diagrams. Amongst the different combinations, Oleic 
acid with Labrasol and PEG 6000 at the Smix ratio of 3:1 was able to 
give a maximal region for stable nano/microemulsion.  
Design of experiment 
The application of DOE tools is important in achieving quality within 
the product with minimal experimentation. Hence, Mixture design 
was employed for 3 factors (oil, surfactant and cosurfactant) and 4 
responses (particle size, emulsification time, drug loading and % 
drug release) and the extreme values drawn from the phase diagram 
was specified in the design along with the required target values for 
the responses. Within a few steps of computing the formulation 
trials initially, an optimal design was selected under mixture design 
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for which randomized run order of 8 default runs was generated by 
the software. The characterization report obtained for the prepared 
formulations was integrated to the design matrix in order to plot the 
known responses and also mainly to predict the not formulated and 
non-evaluated intermediate combinations of the excipients and to 
predict a continuous response curve which was later used in 
optimizing and validating the best formulations with best outcomes.  
Characterization of formulations  
Droplet size distribution is one of the stability-indicating 
characteristics of the emulsion. The mean droplet size obtained for 
all eight formulations was in the range of 257.1 to 667.9 nm. Smaller 
the droplet size, better is the absorption of the drug and enhances 
the bioavailability of drug product. The in vitro assessment of self-
emulsification was carried out to ensure, the SMEDDS on contact 
with GI fluids will undergo emulsification spontaneously. The 
emulsification time required for all the formulations was less than 1 
min indicates the minimum requirement of free energy for self 
emulsification. The % drug content of all the formulations was found 
to be satisfactory (93.0 to 99.8 %). The in vitro drug release studies 
showed all formulations released more than 74 % of the drug within 
15 min. The formulation EFM8 showed the highest drug release of 
91 %, whereas EFM 7 shows the least % drug release of 74 %. The 
slowdown of drug release may be attributed to reduced diffusion of 
the drug through the lamellar surfactant/cosurfactant layers, which 
also increases the microenvironment viscosity. 
 
Table 5: Mixture design formulations and observed responses 
Formulation Oleic 
acid 
Labrasol PEG 600 Droplet size nm Emulsification 
time sec 
% Drug loading % Drug release at 
15 min 
EFM1 0.116 0.675 0.209 297.84±2.35 26.0±1.0 99.19±0.21 88.74±1.88 
EFM2 0.181 0.626 0.193 310.75±5.87 30.33±0.58 98.90±0.30 86.61±2.45 
EFM3 0.198 0.577 0.225 380.55±5.39 30.33±0.58 98.11±0.10 85.54±1.77 
EFM4 0.132 0.675 0.193 287.28±1.67 27.33±0.58 98.95±0.76 90.16±1.88 
EFM5 0.214 0.577 0.209 589.26±3.48 35.33±0.58 94.18±0.65 75.97±0.62 
EFM6 0.149 0.626 0.225 293.48±4.92 26.0±0.0 99.04±0.56 90.27±0.74 
EFM7 0.23 0.577 0.193 667.74±9.69 40.33±0.58 93.34±0.42 74.78±1.78 
EFM8 0.1 0.675 0.225 257.16±2.45 24.0±1.0 99.83±0.16 91.34±0.54 
*Data expressed as mean±SD (n=3) 
 
Evaluation of model 
The data obtained for all eight formulation batches were integrated in 
the design to check the model fit. The data obtained was analyzed 
statistically by fitting multiple regression models with the intercept set 
to zero. The statistically significant models determined for droplet size 
(nm) (R2= 0.96 and p-0.1022), emulsification time (sec) (R2= 0.99 and 
p-0.0267), % drug loading (R2= 0.93 and p-0.1667) and % drug release 
at 15 min (R2
The effects summary of the whole model was used to investigate the 
effect of independent variables on dependent variables. In the graph, 
the length of each bar shows the effect of variables and the 
magnitude of the effect on the quality attributes. In the effects 
summary table the bar presenting Oleic acid and Labrasol crosses 
the blue vertical line indicating the significance. Hence, the material 
attributes like Oleic acid and Labrasol considered in the design were 
having a significant influence on the responses. 
= 0.96 and p-0.0911) were statistically significant. The 
effects test report and leverage plots obtained for all the individual 
responses considered in the design are presented in table 6 and fig. 4, 
respectively. The effects test report obtained for the droplet size 
indicates Oleic acid (p-0.0069) has a significant effect on the model. 
The emulsification time depends on both Oleic acid (p-0.0006) and 
Labrasol (p-0.0072). The % drug loading is influenced by Oleic acid (p-
0.0002)and Labrasol (p-0.0008), and similarly, the % drug release also 




Fig. 4: Actual Vs predicted plots for dependent variables 
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Table 6: Effects test report for dependent variable 
Source Prob>F 
Droplet size Emulsification time % Drug  load % Drug release at 15 min 
(Oleic acid-0.1)/0.13 0.0069* 0.0006* 0.0002* 0.0010* 
(Labrasol-0.577)/0.13 0.1492 0.0072* 0.0008* 0.0038* 
(PEG 6000-0.193)/0.13 0.4236 0.8434 0.1147 0.1627 
Oleic acid*Labrasol 0.2037 0.1299 0.3043 0.1804 
Oleic acid*PEG 6000 0.4701 0.8075 0.5337 0.3622 






Fig. 5: Leverage plots for dependent variables 
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Source Log worth  P value 
(Oleic acid-0.1)/0.13 3.800  0.00016 
(Labrasol-0.577)/0.13 3.104  0.00079 
(PEG 6000-0.193)/0.13 0.940  0.11474 
Oleic acid*Labrasol 0.886  0.12994 
Labrasol*PEG 6000 0.475  0.33526 
Oleic acid*PEG 6000 0.441  0.36218 
Fig. 6: Effects summary report 
 
Table 7: Summary of the model fit 
Statistical parameters Droplet size (nm)  Emulsification time (sec) % Drug loading % Drug release at 15 min 
R Square 0.957788 0.989247 0.929641 0.962495 
R Square Adj 0.852257 0.962366 0.753744 0.868733 
Root Mean Square Error 59.74549 1.040833 1.285697 2.548653 
Mean of Response 385.575 29.75 97.59875 85.505 
Observations (or Sum Wgts) 8 8 8 8 
 
Design verification 
The design validation was carried out by conducting the 
experimental batch as per the Ternary mixture profiler (fig. 7). The 
results obtained for the verification formulation (VF) are presented 
in table 8 and compared with the predicted values as per the 
profiler. The numerical immediacy was observed between the 
predicted and the observed value and indicates validity of the model. 
 
Table 8: Composition of VF and of RTV-SMEDDS 
Formulation Oleic acid Labrasol PEG 6000 
VF-ETV-SMEDDS 0.130 0.652 0.218 
OF-ETV-SMEDDS 0.117 0.659 0.224 
 
 
Fig. 7: Mixture profiler report 
 
Optimization of formulation 
The global desirability function obtained through the prediction profiler 
was utilized for the simultaneous optimization of ETV-SMEDDS. The 
prediction profiler shows a continuous correlation between multiple 
factors and multiple responses, giving a complete picture of the 
variability possible within the selected extreme values. The maximal 
global desirability value was found to be 0.9415. The global desirability 
values indicates that the selected factors and responses have a good 
correlation and are significant enough for optimization and prediction of 
best formulation. The predicted values of droplet size, emulsification 
time, % drug loading and % drug release at 15 min were 252.55 nm, 
24.39 sec, 99.85 % and 91.605 %, respectively, at oil, surfactant and 
cosurfactant of 0.1169, 0.6594 and 0.2236 respectively. The optimized 
level of factors yielded a formulation with minimal droplet size, faster 
emulsification process, maximum drug loading with the faster release of 
drug from the formulation (table 9). The experimental values and 
predicted values were in close agreement with each other. This showed 
the efficiency of the optimization process in predicting the quality 
attributes of ETV-SMEDD. The zeta potential obtained for the optimized 
formulation indicates the stearic stability of the formulation and the 
report obtained is presented in the fig. 11.  
Hence the studies shows that the development of ETV-SMEDDS by 
the application of QbD concept could be a desirable approach in 
attaining the therapeutic and the formulation goals. 
 
Table 9: Predicted and experimental values obtained for VF-ETV-SMEDDS and OF-ETV-SMEDDS 
Formula
tion 








% Drug loading % 
Differe
nce 
























2.86 25.26 26±0.58 2.9 99.33 98.12±0.8
6 










*Data expressed as mean±SD (n=3) 
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Fig. 8: Prediction profiler 
 
 
Fig. 9: Droplet size report for VF-ETV-SMEDDS 
 
 
Fig. 10: Droplet size report for OF-ETV-SMEDDS 
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Fig. 11: Zeta potential report for OF-ETV-SMEDDS 
 
CONCLUSION 
SMEDDS were a promising approach for the formulation of poorly 
water-soluble drugs. The predetermined quality characteristics of 
ETV-SMEDDS were achieved with the implementation of QbD 
concepts throughout the development process. The detailed analysis 
of the three independent variables called oleic acid, labrasol, PEG 
6000 and their effects on the quality attributes such as droplet size, 
emulsification time, drug loading efficiency and % drug release was 
studied with the application of statistical mixture design. This study 
showed the potential of QbD in SMEDDS development. 
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